The consumption of both OOs improved the proteomic CAD score at endpoint compared with baseline ( mean improvement : -0.3 for low-phenolic OO and -0.2 for high-phenolic OO ; P < 0.01 ) but not CKD or diabetes proteomic biomarkers .